Eran Ovadya
Directeur Financier/CFO chez NUREXONE BIOLOGIC INC.
Fortune : 158 950 $ au 31/05/2024
Profil
Mr. Eran Ovadya is a Chief Financial Officer at NurExone Biologic, Inc. Mr. Ovadya was previously employed as a Chief Financial Officer by Silexion Therapeutics Ltd.
and a Chief Financial Officer by VVT Medical Ltd.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NUREXONE BIOLOGIC INC
0,63% | 16/05/2024 | 425 000 ( 0,63% ) | 158 950 $ | 31/05/2024 |
Postes actifs de Eran Ovadya
| Sociétés | Poste | Début |
|---|---|---|
| NUREXONE BIOLOGIC INC. | Directeur Financier/CFO | 15/06/2022 |
Anciens postes connus de Eran Ovadya
| Sociétés | Poste | Fin |
|---|---|---|
| VVT Medical Ltd. | Directeur Financier/CFO | - |
Silexion Therapeutics Ltd.
 Silexion Therapeutics Ltd. BiotechnologyHealth Technology Silenseed Ltd. operates as a biopharmaceutical company. Its programs include SiG12D-LODER for pancreatic cancer, and Prostate-LODER, GBM-LODER for brain cancer. The company was founded by Dr. Amotz Shemi and Prof. Eithan Galun on November 30, 2008 and is headquartered in Modi’in, Israel. | Directeur Financier/CFO | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NUREXONE BIOLOGIC INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Silexion Therapeutics Ltd.
Silexion Therapeutics Ltd. BiotechnologyHealth Technology Silenseed Ltd. operates as a biopharmaceutical company. Its programs include SiG12D-LODER for pancreatic cancer, and Prostate-LODER, GBM-LODER for brain cancer. The company was founded by Dr. Amotz Shemi and Prof. Eithan Galun on November 30, 2008 and is headquartered in Modi’in, Israel. | Health Technology |
| VVT Medical Ltd. |
